AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10578479 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage containing 20 g of protein and 38 mg of total isoflavones
Number of subjects: 36
Study 8934087 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at ten litres per minute through a specially modified non‐rebreathing mask
Number of subjects: 100
Study 8934087 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen at four litres per minute via nasal specular
Number of subjects: 100
Study 1859515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine for 3 months
Number of subjects: 15
Study 1859515 — intervention group
Group type: COMPARATOR
Intervention: Control group (acetylsalicylic acid + dipyridamol)
Number of subjects: 15
Study 6313596 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (500 mg/m2/dose three times daily for 7 days)
Number of subjects: 20
Study 6313596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine (10 mg/kg/day for 5 days)
Number of subjects: 20
Study 6313596 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (500 mg/m2/dose infused over one hour three times daily for 7 days)
Number of subjects: 20
Study 6313596 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 20
Study 6313596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31200434 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multicomponent physical exercise programme
Number of subjects: 0
Study 27294374 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and sprint interval training (SIT)
Number of subjects: 36
Study 27294374 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and short interval training (INT)
Number of subjects: 36
Study 27294374 — intervention group
Group type: COMPARATOR
Intervention: Strength-only training group (CON)
Number of subjects: 36
Study 26099316 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP blockade using ultrasound guidance
Number of subjects: 226
Study 26099316 — intervention group
Group type: COMPARATOR
Intervention: Control (no TAP blockade)
Number of subjects: 226
Study 24552979 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly minodronate (50 mg)
Number of subjects: 38
Study 24552979 — intervention group
Group type: COMPARATOR
Intervention: Weekly alendronate (35 mg)
Number of subjects: 38
Study 22377800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone administration (25-50 mg at 16:00 and 20:00 h)
Number of subjects: 18
Study 22377800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no progesterone)
Number of subjects: 18
Study 19297462 — intervention group
Group type: COMPARATOR
Intervention: 0 microg vitamin D(3)/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg vitamin D(3)/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg vitamin D(3)/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg vitamin D(3)/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.6 microg/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.2 microg/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 24.7 microg/d
Number of subjects: 225
Study 19297462 — intervention group
Group type: EXPERIMENTAL
Intervention: 38.7 microg/d
Number of subjects: 225
Study 17255295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy before cytokine therapy
Number of subjects: 0
Study 17255295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Number of subjects: 0
Study 17255295 — intervention group
Group type: COMPARATOR
Intervention: Targeted agents for advanced renal cell carcinoma
Number of subjects: 0
Study 15356779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for 14 days
Number of subjects: 60
Study 15356779 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily for 3 days
Number of subjects: 60
Study 11377156 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 24
Study 11377156 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 24
Study 11377156 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isoflurane and propofol anesthesia
Number of subjects: 24
Study 9430327 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal testing
Number of subjects: 41
Study 8276554 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 49
Study 8276554 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 49
Study 8276554 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 49
Study 8276554 — intervention group
Group type: COMPARATOR
Intervention: Spinal and General anaesthesia
Number of subjects: 49
Study 2959719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 30
Study 31468249 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT (Cognitive-Behavioral Therapy)
Number of subjects: 39
Study 31468249 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE-CBT (Cognitive-Behavioral Therapy)
Number of subjects: 39
Study 31468249 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 39
Study 29493373 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVERS
Number of subjects: 0
Study 29493373 — intervention group
Group type: EXPERIMENTAL
Intervention: NONMOVERS
Number of subjects: 0
Study 29493373 — intervention group
Group type: COMPARATOR
Intervention: CONTROLS
Number of subjects: 0
Study 27592487 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol
Number of subjects: 212
Study 27592487 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 212
Study 25447348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) program; 18 visits of aerobic exercise at 60% to 80% of heart rate reserve
Number of subjects: 26
Study 25447348 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 23373233 — intervention group
Group type: EXPERIMENTAL
Intervention: bi yan qing du ke li combined with nasal care
Number of subjects: 60
Study 23373233 — intervention group
Group type: COMPARATOR
Intervention: bi yan qing du ke li
Number of subjects: 60
Study 20644548 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 46
Study 20644548 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg daily
Number of subjects: 46
Study 18001721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d orally; group A)
Number of subjects: 110
Study 18001721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet per d; group B)
Number of subjects: 110
Study 15954870 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg misoprostol intravaginally
Number of subjects: 77
Study 15954870 — intervention group
Group type: COMPARATOR
Intervention: Gentle cervical assessment only
Number of subjects: 77
Study 12801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 8
Study 12801953 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 8
Study 12579104 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (24.34 mEq or 3 g in 100 mL saline solution administered over 2 hours preoperatively, perioperatively, and on postoperative days 0, 1, 2, and 3)
Number of subjects: 200
Study 12579104 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (100 mL administered according to the same schedule as treatment group)
Number of subjects: 200
Study 12579104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 200
Study 9523374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral baclofen administered for 14 days
Number of subjects: 2
Study 9523374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 7644831 — intervention group
Group type: EXPERIMENTAL
Intervention: audio‐auditory (auditory rhythms combined with an auditory model)
Number of subjects: 0
Study 7644831 — intervention group
Group type: EXPERIMENTAL
Intervention: audio‐visual (auditory rhythms combined with a visual model)
Number of subjects: 0
Study 7644831 — intervention group
Group type: EXPERIMENTAL
Intervention: auditory only (auditory rhythms with no model)
Number of subjects: 0
Study 7644831 — intervention group
Group type: EXPERIMENTAL
Intervention: visual only (no auditory rhythms but exposure to a visual model)
Number of subjects: 0
Study 2655690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (CyA) with erythromycin
Number of subjects: 0
Study 2655690 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (CyA) without erythromycin
Number of subjects: 0
Study 793842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate, 400 mg
Number of subjects: 8
Study 793842 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital, 60 mg
Number of subjects: 8
Study 793842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate and phenobarbital in combination
Number of subjects: 8
Study 793842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31290104 — intervention group
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 234
Study 31290104 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 234
Study 31290104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 234
Study 28267071 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration anesthesia (DentalVibe device)
Number of subjects: 25
Study 28267071 — intervention group
Group type: COMPARATOR
Intervention: Sham (device off)
Number of subjects: 25
Study 28267071 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sham vs intervention
Number of subjects: 25
Study 26843724 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of instant coffee divided into three portions right after removing the nasogastric tube, first postoperative day
Number of subjects: 61
Study 26843724 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of tea
Number of subjects: 61
Study 26843724 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of instant coffee
Number of subjects: 61
Study 24075659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate force (50-g force applied bilaterally to the first premolars for 1, 4, 8, or 12 weeks)
Number of subjects: 27
Study 24075659 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe force (300-g force applied bilaterally to the first premolars for 1, 4, 8, or 12 weeks)
Number of subjects: 27
Study 24075659 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 subjects)
Number of subjects: 27
Study 21804130 — intervention group
Group type: EXPERIMENTAL
Intervention: torcetrapib plus atorvastatin
Number of subjects: 6661
Study 21804130 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 6661
Study 19509505 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 6
Study 19509505 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (75 microg kg(‐1))
Number of subjects: 6
Study 16460338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine alone (0.75% ropivacaine, 1.8 ml)
Number of subjects: 32
Study 16460338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine + epinephrine (1.8 ml)
Number of subjects: 32
Study 15488338 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation stage of change
Number of subjects: 322
Study 15488338 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontemplators
Number of subjects: 322
Study 15488338 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptom severity and history of recurrent depressive episodes
Number of subjects: 322
Study 11789710 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health counselling
Number of subjects: 268
Study 11789710 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 268
Study 9032501 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 month rehabilitation programme including drug treatment
Number of subjects: 0
Study 9032501 — intervention group
Group type: COMPARATOR
Intervention: Control period of drug treatment only
Number of subjects: 0
Study 8320490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous deferoxamine (DFO) at 180 mg/kg/day
Number of subjects: 6
Study 8320490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous deferoxamine (DFO) at 150 mg/kg/day for 3 months
Number of subjects: 6
Study 3560265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit maintained near 30% (n = 12)
Number of subjects: 25
Study 3560265 — intervention group
Group type: COMPARATOR
Intervention: Hematocrit maintained near 40% (n = 13)
Number of subjects: 25
Study 3560265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (30% and 40% HCT)
Number of subjects: 25
Study 31221106 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH intervention (community-based health-promoting school intervention)
Number of subjects: 0
Study 31221106 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH intervention
Number of subjects: 0
Study 31221106 — intervention group
Group type: COMPARATOR
Intervention: Control schools (four control schools)
Number of subjects: 0
Study 29272301 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude training (30 minutes/day, five days/week for six weeks)
Number of subjects: 38
Study 29272301 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (stretch and relaxation exercises at equal intensity)
Number of subjects: 38
Study 26004980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment adherence at six months assessment
Number of subjects: 1154
Study 26004980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment adherence at twelve months assessment
Number of subjects: 1154
Study 23698210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite group (20 patients)
Number of subjects: 40
Study 23698210 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 40
Study 21945448 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate pentahydrate (CLP)
Number of subjects: 15
Study 21945448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium linear polyphosphate (LPP)
Number of subjects: 15
Study 21945448 — intervention group
Group type: EXPERIMENTAL
Intervention: CLP + LPP
Number of subjects: 15
Study 21945448 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan gum (XG)
Number of subjects: 15
Study 21945448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tripolyphosphate (STP)
Number of subjects: 15
Study 21945448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pyrophosphate tetrabasic (PP)
Number of subjects: 15
Study 21945448 — intervention group
Group type: COMPARATOR
Intervention: Pure orange juice (C-)
Number of subjects: 15
Study 21945448 — intervention group
Group type: COMPARATOR
Intervention: Calcium-modified juice (C+)
Number of subjects: 15
Study 19793095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 100
Study 19793095 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 2% cream
Number of subjects: 100
Study 17893603 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: basiliximab, TAC (0.05 mg/kg twice daily) plus MMF (1 g twice daily)
Number of subjects: 240
Study 17893603 — intervention group
Group type: COMPARATOR
Intervention: Group A: Thymoglobulin, CsA (4 mg/kg twice daily) plus azathioprine (1.5 mg/kg once daily)
Number of subjects: 240
Study 17893603 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: basiliximab, CsA (2 mg/kg twice daily) plus MMF (1 g twice daily)
Number of subjects: 240
Study 17893603 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 240
Study 17893603 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 240
Study 17893603 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 240
Study 17893603 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 15089813 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (600 mg)
Number of subjects: 0
Study 15089813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11903524 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40
Study 11903524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9972405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg intravenously)
Number of subjects: 20
Study 9972405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8067552 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.15 mg/kg intravenously
Number of subjects: 90
Study 8067552 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.25 mg/kg intravenously
Number of subjects: 90
Study 8067552 — intervention group
Group type: COMPARATOR
Intervention: normal saline 0.3 mL/kg (Control)
Number of subjects: 90
Study 3054622 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (116.75 mg/day)
Number of subjects: 40
Study 3054622 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (116.25 mg/day)
Number of subjects: 40
Study 31155764 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with prophylactic protocol and monitoring (enzyme declogging kits administered every 7 days for 4 weeks)
Number of subjects: 49
Study 31155764 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 49
Study 31155764 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with prophylactic protocol and monitoring (enzyme declogging kits)
Number of subjects: 49
Study 28609319 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone 20 mg
Number of subjects: 62
Study 28609319 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone 40 mg
Number of subjects: 62
Study 28609319 — intervention group
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide 20 mg
Number of subjects: 62
Study 28609319 — intervention group
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide 40 mg
Number of subjects: 62
Study 28609319 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 62
Study 28739492 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30±5.8 mg/d)
Number of subjects: 75
Study 28739492 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (94.0±40.4 mg/d)
Number of subjects: 75
Study 28739492 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5.2±1.6 mg/d)
Number of subjects: 75
Study 25688740 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 569
Study 25688740 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 569
Study 24038103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (specifics not provided)
Number of subjects: 354
Study 24038103 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 354
Study 24038103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor grading, tumor size, lymph node involvement
Number of subjects: 354
Study 24038103 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (implied control group)
Number of subjects: 354
Study 21925353 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic scores using miniature sensors (3-dimensional gyroscopes and accelerometers)
Number of subjects: 34
Study 21925353 — intervention group
Group type: COMPARATOR
Intervention: Regular outcome scores (SST, Disabilities of the Arm, Shoulder and Hand, American Shoulder and Elbow Surgeons, Constant)
Number of subjects: 34
Study 18954621 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin sealant applied along the staple lines on one side
Number of subjects: 25
Study 18954621 — intervention group
Group type: COMPARATOR
Intervention: No additional measure taken on the other side (Control)
Number of subjects: 25
Study 18954621 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin sealant
Number of subjects: 25
Study 16565560 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) treatment, subcutaneously injected once a day for 10 days at a low dose.
Number of subjects: 46
Study 16565560 — intervention group
Group type: COMPARATOR
Intervention: Non-G-CSF control group.
Number of subjects: 46
Study 12603186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 100 microg daily
Number of subjects: 3
Study 12603186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 1000 microg daily
Number of subjects: 3
Study 12603186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 2000 microg daily
Number of subjects: 3
Study 10926069 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine intra‐articularly (group 1)
Number of subjects: 60
Study 10926069 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg clonidine intra‐articularly (group 2)
Number of subjects: 60
Study 10926069 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine + 150 microg clonidine intra‐articularly (group 3)
Number of subjects: 60
Study 10926069 — intervention group
Group type: COMPARATOR
Intervention: Normal saline intra‐articularly (group 4)
Number of subjects: 60
Study 8724108 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL-D9N mutation carriers (cases)
Number of subjects: 0
Study 8724108 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-carriers (cases)
Number of subjects: 0
Study 8724108 — intervention group
Group type: COMPARATOR
Intervention: LPL-D9N mutation carriers (controls)
Number of subjects: 0
Study 8724108 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers (controls)
Number of subjects: 0
Study 8724108 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL-D9N mutation carriers (cases and controls with BMI > 26.0 kg/m2)
Number of subjects: 0
Study 1570800 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet
Number of subjects: 21